AgeX Therapeutics, Inc. (AGE)

-0.010 (-1.82%)
Nov 29, 2022 3:59 PM EDT - Market closed

Company Description

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States.

The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease.

Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology.

The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases.

AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.

AgeX Therapeutics, Inc.
AgeX Therapeutics logo
Country United States
Founded 2017
IPO Date Nov 29, 2018
Industry Biotechnology
Sector Health Care
Employees 5
CEO Michael West

Contact Details

1101 Marina Village Parkway
Alameda, California 94501
United States
Phone 510 671 8370

Stock Details

Ticker Symbol AGE
Fiscal Year End December
Reporting Currency USD
CIK Code 0001708599
CUSIP Number 00848H108
ISIN Number US00848H1086
Employer ID 82-1436829
SIC Code 2834

Key Executives

Name Position
Dr. Michael D. West Ph.D. Founder, President, Chief Executive Officer and Director
Eun-Jae Park CPA Chief Financial Officer
Dr. Nafees Naseer Malik M.D. Chief Operating Officer
Dr. Ivan Labat Chief Information Officer
Judith Segall Secretary

Latest SEC Filings

Date Type Title
Nov 25, 2022 8-K Current Report
Nov 10, 2022 8-K Current Report
Nov 10, 2022 10-Q Quarterly Report
Nov 2, 2022 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Nov 2, 2022 DEF 14A Other definitive proxy statements
Oct 25, 2022 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Oct 21, 2022 8-K Current Report
Oct 5, 2022 PRER14A Filing
Sep 16, 2022 PRE 14A Other preliminary proxy statements
Aug 23, 2022 SC 13D/A [Amend] General statement of acquisition of beneficial ownership